83 related articles for article (PubMed ID: 31273434)
1. Exceptional 4-year response to
Gafita A; Wang H; Tauber R; D'Alessandria C; Weber WA; Eiber M
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2212-2213. PubMed ID: 31273434
[No Abstract] [Full Text] [Related]
2. Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy.
Santo G; Di Santo G; Zelger B; Virgolini I
Nuklearmedizin; 2024 Jun; 63(3):219-220. PubMed ID: 38190993
[No Abstract] [Full Text] [Related]
3. The Imperative for Comparative Studies in Nuclear Medicine: Elevating
Rahbar K; Boegemann M
J Nucl Med; 2024 Feb; 65(2):224-225. PubMed ID: 38176720
[No Abstract] [Full Text] [Related]
4. Management of Dry Eye Toxicity After Treatment With
Pepin A; Lee V; O'Brien S; Mulugeta P; Taunk NK
Pract Radiat Oncol; 2024; 14(4):301-304. PubMed ID: 38631608
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225 Ac-PSMA-617.
Yang H; Zhang Y; Su D; Zhang Y; Chen Y
Clin Nucl Med; 2023 Dec; 48(12):1078-1081. PubMed ID: 37796187
[TBL] [Abstract][Full Text] [Related]
6. 177 Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer.
Qu G; Hua Q; Li H; Zhang Y; Chen Y
Clin Nucl Med; 2024 Feb; 49(2):152-153. PubMed ID: 38170913
[TBL] [Abstract][Full Text] [Related]
7. An Intrapatient Dosimetry Comparison of
Rinscheid A; Gäble A; Wienand G; Pfob C; Dierks A; Kircher M; Trepel M; Weckermann D; Lapa C; Bundschuh RA
J Nucl Med; 2023 Dec; 64(12):1918-1924. PubMed ID: 37770108
[TBL] [Abstract][Full Text] [Related]
8. Image-Guided Fine-Needle Aspiration Cytology for BRCA Mutation Assessment of PSMA-Positive Lymph Node Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer.
Werner A; Seifert P; Theis B; Freesmeyer M; Leder T
Clin Nucl Med; 2023 Dec; 48(12):1049-1050. PubMed ID: 37801600
[TBL] [Abstract][Full Text] [Related]
9. Joint EANM/SNMMI procedure guideline for the use of
Kratochwil C; Fendler WP; Eiber M; Hofman MS; Emmett L; Calais J; Osborne JR; Iravani A; Koo P; Lindenberg L; Baum RP; Bozkurt MF; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen WJG; Rahbar K; Schoder H; Virgolini I; Bodei L; Fanti S; Haberkorn U; Hermann K
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2830-2845. PubMed ID: 37246997
[TBL] [Abstract][Full Text] [Related]
10. Combining enzalutamide and [
Houédé N; Hebert K
Lancet Oncol; 2024 May; 25(5):531-533. PubMed ID: 38621399
[No Abstract] [Full Text] [Related]
11. Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177 Lu- PSMA-617 radioligand therapy using quantitative SPECT-CT at single time point: a single-center feasibility study.
Kaur K; Nagi S; Satapathy S; Aggarwal P; Sood A; Mittal BR
Nucl Med Commun; 2024 Feb; 45(2):115-120. PubMed ID: 37982573
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Metastasis From Prostate Cancer on Posttherapeutic 177 Lu-Prostate-Specific Membrane Antigen Scan.
Taghavi M; Ahmadi R; Qutbi M
Clin Nucl Med; 2024 May; 49(5):e217-e218. PubMed ID: 38409757
[TBL] [Abstract][Full Text] [Related]
13. Isolated Adrenal Metastases of Castration-Resistant Prostate Cancer: Excellent Response to 177 Lu-PSMA With No Adrenal Insufficiency.
Topal E; Has Simsek D; Vatansever S; Sanli Y; Kuyumcu S
Clin Nucl Med; 2024 Jan; 49(1):e8-e9. PubMed ID: 37991439
[TBL] [Abstract][Full Text] [Related]
14. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going.
Muniz M; Loprinzi CL; Orme JJ; Koch RM; Mahmoud AM; Kase AM; Riaz IB; Andrews JR; Thorpe MP; Johnson GB; Kendi AT; Kwon ED; Nauseef JT; Morgans AK; Sartor O; Childs DS
Cancer Treat Rev; 2024 Jun; 127():102748. PubMed ID: 38703593
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical
Tishchenko VK; Vlasova OP; Lebedeva AA; Fedorova AV; Pankratov AA; Morozova NB; Kuzenkova KA; Stepchenkova ED; Shegai PV; Ivanov SA; Kaprin AD
Bull Exp Biol Med; 2023 Dec; 176(2):224-226. PubMed ID: 38191882
[TBL] [Abstract][Full Text] [Related]
16. Quadruplet Therapy in De Novo High-Volume Mixed Neuroendocrine Prostate Cancer Using 177Lu-PSMA: A Case Report.
Askari E; Aryana K; Jafarian AH; Bari A; Barashki S
Clin Nucl Med; 2024 Mar; 49(3):e120-e122. PubMed ID: 38306385
[TBL] [Abstract][Full Text] [Related]
17. Alpha emitter isotopes and PSMA ligands: the near future therapeutic prospective for castration-resistant prostate cancer.
Volpe F; Piscopo L; Zampella E; Klain M
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1207-1209. PubMed ID: 38141070
[No Abstract] [Full Text] [Related]
18. Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.
Wang JS; Wong T; Wu KA; Mullikin TC; Armstrong A
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38395466
[TBL] [Abstract][Full Text] [Related]
19. Urinary excretion kinetics of [
de Bakker M; Dominicus N; Meeuwis A; Janssen M; Konijnenberg MW; Nagarajah J; Peters SMB
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3572-3575. PubMed ID: 37421427
[TBL] [Abstract][Full Text] [Related]
20. Dual 177 Lu-Prostate-Specific Membrane Antigen and 177 Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation.
Beyhan E; Erol Fenercioğlu Ö; Şahin R; Çermik TF; Ergül N
Clin Nucl Med; 2024 May; 49(5):447-448. PubMed ID: 38409763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
